SU14813 is a potent multi-targeted tyrosine kinase inhibitor with antiangiogenic and antitumor properties, exhibiting IC50 values in the low nanomolar range against VEGFR1, VEGFR2, PDGFRbeta, and KIT. It has demonstrated efficacy in both in vitro assays and in vivo tumor models, making it a valuable research tool for studying angiogenesis and oncology.